HHLA3: A Protein Involved in Cell Adhesion and Cancer Development

Target Name: HHLA3

NCBI ID: G11147

HHLA3

HHLA3: A Protein Involved in Cell Adhesion and Cancer Development

HHLA3 (HERV-H LTR-associating protein 3 (isoform 2)) is a protein that is expressed in a variety of tissues, including the liver, lung, and heart. It is a member of the HMLA family, which is characterized by the presence of a unique nucleotide-binding oligomerization domain (NBD) in the protein.

HHLA3 is involved in a number of cellular processes that are important for its cell type. For example, it is known to be involved in the regulation of cell adhesion, and has been shown to play a role in the development and progression of certain diseases, such as cancer.

In addition to its role in cellular processes, HHLA3 is also a potential drug target. Its NBD has been shown to be involved in the regulation of various cellular processes, including cell adhesion and differentiation, which makes it a promising target for small molecules.

One potential approach to targeting HHLA3 is to use small molecules that can modulate its NBD activity. This could involve using drugs that bind to specific NBD domains within the protein, or inhibiting the activity of NBD-interactive proteins that are known to interact with HHLA3.

Another approach to targeting HHLA3 is to use antibodies that can specifically recognize and label the protein. This would allow researchers to study its structure and function, and could potentially lead to the development of new treatments for diseases that are caused by the disruption of HHLA3.

Overall, HHLA3 is a protein that is involved in a number of important cellular processes, and has the potential to be a drug target or biomarker. Further research is needed to fully understand its role in disease, and to develop new treatments based on its unique properties.

Protein Name: HERV-H LTR-associating 3

The "HHLA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HHLA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets